Michael A. Lanphere is VP at TransBiotec, Inc. (IMLE). They have made 1 open-market trade across 1 company since 2019, most recently 2019-08-28.
CIK 0001630553
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $521K since 2019, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| IMLE | 50,144,878 | — |
Shares reported on the most recent Form 4, priced at the 2019-09-17 close. 1 holding could not be priced and is excluded from the total.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| IMLE | BUY | 2019-08-28 | 2019-09-17 | $0.10 | $521K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.